BioTuesdays

Author - Sydney Stewart

HCW starts Corcept Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...

Spartan Bioscience

Spartan Bioscience boosts executive team

Closely-held Spartan Bioscience named Blaine Fitzgerald, former VP of finance for Shopify, as CFO. In addition, the company appointed Steve Edgett as EVP to lead its international business development and strategic...

Subscribe

Sign up to our weekly BioTuesdays newsletter.